Novo Nordisk launches head-to-head trial with Eli Lilly as weight loss rivalry heats up
As Eli Lilly launches its newly approved weight loss med Zepbound to much fanfare, Novo Nordisk is tossing a next-gen candidate in the ring.
The Danish pharma company is launching a Phase III head-to-head trial comparing Zepbound (tirzepatide) to its experimental CagriSema, which combines Novo’s blockbuster Wegovy (semaglutide) with the experimental long-acting amylin analog cagrilintide. The study will enroll 800 patients, with an estimated completion in the second half of 2025, according to a listing on clinicaltrials.gov.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.